Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vertex Pharmaceuticals

501.15
+2.290.46%
Post-market: 501.800.6500+0.13%19:58 EDT
Volume:1.65M
Turnover:828.23M
Market Cap:128.84B
PE:-240.94
High:509.00
Open:505.86
Low:498.03
Close:498.86
Loading ...

Vertex Pharmaceuticals Says EU Approves Kaftrio Label Expansion in Cystic Fibrosis

MT Newswires Live
·
08 Apr

Vertex Pharmaceuticals announces EC approval of expanded KAFTRIO label

TIPRANKS
·
08 Apr

European Commission Approves Expanded Label for Kaftrio® in Combination With Ivacaftor for People With Cystic Fibrosis

THOMSON REUTERS
·
08 Apr

European Commission Approves Expanded Label for KAFTRIO® in Combination With Ivacaftor for People With Cystic Fibrosis

Business Wire
·
08 Apr

US High Growth Tech Stocks To Watch Now

Simply Wall St.
·
07 Apr

2 Stocks to Buy if You're Worried About a Recession

Motley Fool
·
07 Apr

11 Stocks to Buy After the Biotech Bloodbath -- Barrons.com

Dow Jones
·
04 Apr

Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know

Zacks
·
04 Apr

Q4 Earnings Outperformers: Amgen (NASDAQ:AMGN) And The Rest Of The Therapeutics Stocks

StockStory
·
03 Apr

Is Vertex Pharmaceuticals Incorporated (VRTX) the Best Gene-Editing Stock to Buy?

Insider Monkey
·
02 Apr

Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital

Dow Jones
·
02 Apr

Biotech stocks slide as Marks resignation seen being negative for sector

TipRanks
·
01 Apr

VRTX Provides Mixed Updates for Type 1 Diabetes Pipeline Candidates

Zacks
·
01 Apr

RBC Adjusts Price Target on Vertex Pharmaceuticals to $420 From $408, Maintains Sector Perform Rating

MT Newswires Live
·
01 Apr

BUZZ-RBC raises Vertex PT, expects strong start for cystic fibrosis drug

Reuters
·
01 Apr

Vertex Pharmaceuticals Inc : RBC Raises Target Price to $420 From $408

THOMSON REUTERS
·
01 Apr

Vertex Pharmaceuticals (VRTX) Gets a Hold from Bernstein

TIPRANKS
·
01 Apr

Evercore ISI Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
01 Apr

Vertex Pharmaceuticals Inc. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
01 Apr

Intellia Focuses on Pipeline Development Amid Stiff Competition

Zacks
·
31 Mar